Search

Additional file 6. Hematology results from toxicity study. White blood cells (WBC), lymphocytes (LY), monocytes (MO), granulocytes (GR), red blood cells (RBC) and red blood cell distribution width (RDW), hematocrits (Hct), platelets (Plt), haemoglobin (Hgb), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin count (MCHC) and mean corpuscular volume (MCV) measurements from the IRDye800CW-nimotuzumab (800CW-Nz) toxicity studies.

Additional file 1. Clinical trials by probe. A table listing the clinical trials by probe with IRDye800CW and the number (n) of clinical trials.

Additional file 6. Hematology results from toxicity study. White blood cells (WBC), lymphocytes (LY), monocytes (MO), granulocytes (GR), red blood cells (RBC) and red blood cell distribution width (RDW), hematocrits (Hct), platelets (Plt), haemoglobin (Hgb), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin count (MCHC) and mean corpuscular volume (MCV) measurements from the IRDye800CW-nimotuzumab (800CW-Nz) toxicity studies.

Additional file 9. Clinical trials by probe and trial status. A table listing clinical trials by probe of probes similar to IRDye800CW-nimotuzumab showing trials ‘completed’, ‘in progress’ and ‘terminated’ or ‘withdrawn’.

Additional file 8. Indications of clinical trials with IRDye800CW. A table listing the clinical trials, indications and the number of indications (n).

Additional file 4. Weight of mouse liver, kidney, and spleen from toxicity studies. Graphs showing the weights of the liver, spleen and kidney of the mice used for the toxicity experiments.

Additional file 5. Clinical chemistry results from the toxicity study. Sodium, potassium, sodium: potassium (Na:K) ratio, chloride, calcium, phosphorus magnesium, urea, creatinine, amylase, lipase, glucose, cholesterol, bilirubin, alkaline phosphatase (Alk Phos), alanine aminotransferase (ALT), glutamate dehydrogenase (GLDH), CK (creatine kinase), protein, albumin, globulin and albumin:globulin (A:G) ratio measurements from the IRDye800CW-nimotuzumab (800CW-Nz) toxicity studies.

Additional file 7. Table 2: Clinical trials on clinicaltrials.gov accessed 20,190,422 search term: “800CW OR IRDYE800CW OR IRDYE”.

Additional file 9. Clinical trials by probe and trial status. A table listing clinical trials by probe of probes similar to IRDye800CW-nimotuzumab showing trials ‘completed’, ‘in progress’ and ‘terminated’ or ‘withdrawn’.

Additional file 5. Clinical chemistry results from the toxicity study. Sodium, potassium, sodium: potassium (Na:K) ratio, chloride, calcium, phosphorus magnesium, urea, creatinine, amylase, lipase, glucose, cholesterol, bilirubin, alkaline phosphatase (Alk Phos), alanine aminotransferase (ALT), glutamate dehydrogenase (GLDH), CK (creatine kinase), protein, albumin, globulin and albumin:globulin (A:G) ratio measurements from the IRDye800CW-nimotuzumab (800CW-Nz) toxicity studies.

Additional file 7. Table 2: Clinical trials on clinicaltrials.gov accessed 20,190,422 search term: “800CW OR IRDYE800CW OR IRDYE”.

Additional file 3. Mouse weights from toxicity studies. Graphs showing the weights of the mice used for the toxicity experiments prior to and during the experiments.

Additional file 4. Weight of mouse liver, kidney, and spleen from toxicity studies. Graphs showing the weights of the liver, spleen and kidney of the mice used for the toxicity experiments.

Additional file 2. Schematic of how the meta-analysis on clinical trials with IRDye800CW was done and tables showing the clinical trials with IRD800CW with results published on pubmed.